[The use of the delayed-action form of korinfar in arterial hypertension, stenocardia and hypertrophic cardiomyopathy].
Corinfar-retard (CR) was tried in 146 patients, the acute test was performed in 26 cases. The findings confirm antihypertensive activity of the drug, reduced frequency of sharp changes in blood pressure and of hypertensive crises, side effects, its ability to diminish platelet aggregation. As for coronary heart disease. CR is more beneficial in non-severe angina of effort, spontaneous angina, associated hypertension. In hypertrophic cardiomyopathy prolonged administration of CR resulted in moderate subjective response. A CR two-month course did not induce noticeable changes in serum lipids. Hypertensive subjects on the acute test improved some hemodynamic and diastolic parameters.